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Objective: Many reports have raised certain problems concerning the current TNM
classification of lung cancer, namely that there is no sufficient difference in prog-
nosis between patients with pathologic stage IIIA and IIIB disease. For clarifying
this problem, the present study was constructed in light of T3 and T4 classifications.
Methods: Among 429 patients with non–small cell lung cancer who underwent
resection, those with stage IIIA (n  73) and stage IIIB (n  79) disease were
enrolled in this study, and their prognostic factors were compared.
Results: No difference in the survivals between patients with T3 and T4 disease was
observed, and this seemed to affect the prognoses of patients with stage IIIA and
IIIB disease. However, when those with T3 and T4 disease were classified into different
groups on the basis of TNM descriptors, differences in the survivals became evident.
The T3 bronchial invasion group showed a better prognosis than the T3 extrapulmonary
invasion group. The T4 tracheal invasion group and T4 pulmonary metastasis group
showed a significantly better prognosis than that in the T4 extrapulmonary invasion
group and the T4 malignant pleural exudate group. The surgical curativity of patients
with T3 disease was evaluated as curative resection or noncurative resection, and the
surgical curativity of T4 was evaluated as R0 resection or R1 or R2 resection. The T3
bronchial invasion group included more curative resection cases. The T4 tracheal
invasion group and T4 pulmonary metastasis group included more R0 resection cases.
Furthermore, when patients with T3 to T2 bronchial invasion and patients with T4
tracheal invasion and T4 pulmonary metastasis were reclassified as having T3 disease,
the survivals of the patients reclassified as having T3 and T4 disease, as well as the
resultant subsets having stage IIIA and IIIB disease, were significantly different.
Conclusion: Tumor status should be reviewed by taking into account the surgical
curativity.
There have been many reports that the current TNM classification oflung cancer, revised in 1997,1 fails to sufficiently differentiate be-tween the prognoses of patients with pathologic stage IIIA and IIIBdisease.2-4 This might be attributable to the classification method oftumor status, especially T3 and T4. Both these groups comprisepatients with significantly different degrees of surgical curativity.
The heterogeneity of the disease stages within the T3 and T4 groups causes
difficulties in determining patient prognosis in these groups. In the present study we
reviewed the revised TNM classification, with emphasis on patients with non-small
cell lung cancer classified as having stage IIIA and IIIB disease, as well as patients
with tumors designated as T3 and T4.
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Methods
From November 1983 to the end of December 2000, 604 patients
underwent resection of primary lung cancer at our department. Of
these, 429 with non–small cell lung cancer that could be classified
according to the TNM evaluation method into pathologic stages
ranging from I to III were enrolled in the study. Those who died of
other diseases were excluded. Of the 429 patients, 168 had squa-
mous cell carcinoma, 221 had adenocarcinoma, 17 had large cell
lung cancer, and 23 had other types of cancer. Staging of disease
in these patients was as follows: 222 patients had stage I, 55 had
stage II, and 152 had stage III disease (Table 1). Any separate
tumor nodule was considered as intrapulmonary metastasis (PM).
PM in the same lobe of the primary tumor was defined as PM1, and
PM in a different lobe was defined as PM2. Resection was con-
sidered as R0 when there was no residual tumor microscopically,
macroscopically, or both,1 and resection was considered as cura-
tive when (1) the tumor did not extend beyond the visceral pleura
or the resection line of the bronchus, (2) no mediastinal lymph
node metastasis was detected, and (3) pulmonary resection with
complete dissection of mediastinal lymph nodes was performed.5
Survivals on the basis of the TNM classification were analyzed by
using the Kaplan-Meier method,6 and the differences in survivals
were tested with a log-rank test.7 The prognostic factors were
analyzed with the Cox proportional hazards regression model.8
Any difference between 2 factors was tested with the 2 or Fisher
exact tests.
Results
The 5-year survivals of the patients classified according to
pathologic stages I, II, and III were 71.2%, 44.0%, and
23.5%, respectively. Significant differences were observed
between patients with stage I and II disease and between
patients with stage II and III disease (P  .001 and P 
.010, respectively). When disease was subclassified into
stages IA, IB, IIA, IIB, IIIA, and IIIB, the 5-year survivals
of the patients with stage IA and IB disease were 82.1% and
57.8%, respectively, indicating a significant difference in
the prognosis (P  .001). The 5-year survivals of the
patients with stage IIA and IIB disease were 58.3% and
39.6%, respectively. There was a tendency to produce a
significant difference in the prognoses, but statistical signif-
icance was not obtained (P  .175). This might be caused
by the small number of patients with IIA disease (n  12).
The 5-year survivals of the patients with stage IIIA and IIIB
disease were 25.2% and 22.5%, respectively, and no signif-
icant difference was observed between these 2 groups (P 
.114, Figure 1).
The survival curves of the patients classified according to
the tumor status showed that the 5-year survivals of patients
with T1, T2, T3, and T4 disease were 71.8%, 47.2%, 26.1%,
and 21.5%, respectively. Significant differences in progno-
sis were observed between the patients with T1 and T2
disease, as well as between the patients with T2 and T3
disease. However, there was no significant difference be-
tween the patients with T3 and T4 disease (Figure 2). The
survival curves of the patients classified according to the
nodal status showed that the 5-year survivals of patients
with N0, N1, N2, and N3 disease were 62.9%, 50.0%,
19.4%, and 16.7%, respectively. The patients with N0 and
N1 disease showed a tendency to exhibit a prognostic dif-
ference (P  .084). Significant differences were observed
between the patients with N1 and N2 disease, as well as
between the patients with N2 and N3 disease (P  .001 and
P  .002, respectively). These findings suggest that the
absence of a significant difference between the prognoses of
Figure 1. Postoperative survival curves of patients with stage IIIA and IIIB disease.There is no tendency toward
difference between the prognosis of patients with stage IIIA and IIIB disease.
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patients with stage IIIA and IIIB disease might be due, at
least in part, to the tumor status, T3 and T4 in particular.
Analysis was further carried out with the Cox propor-
tional hazards regression model to find out which factors
indicated poor prognosis. The patients’ age (60 years and
60 years), sex, surgical curativity, and tumor and nodal
status were used as covariates. The tumor status was sig-
nificant in indicating poor prognosis for patients with stage
I to III disease, with a hazard ratio of 1.545 (Table 2).
Nevertheless, the tumor status was not recognized as a
significant poor prognostic indicator for stage III disease
alone (Table 3).
Patients with T3 and T4 tumors were subjected to further
study. T3 tumors, classified according to invasion or me-
tastasis sites, were divided into patients with bronchial
invasion and patients with extrapulmonary invasion. One
patient with both bronchial invasion and extrapulmonary
invasion was excluded. Patients with T4 tumors were di-
vided into patients with tracheal invasion, patients with
PM1, patients with extrapulmonary invasion, and patients
with malignant pulmonary exudate, including pleural dis-
semination (Table 4). Seven patients involved in 2 or more
categories were excluded. The survival curves showed that
the 5-year survivals of the patients with T3 bronchial inva-
sion and the patients with T3 extrapulmonary invasion were
43.8% and 22.2%, respectively, indicating a tendency to
exhibit a difference (Figure 3, A). The 5-year survivals of
the patients with T4 tracheal invasion, patients with T4
PM1, patients with T4 extrapulmonary invasion, and pa-
tients with T4 malignant exudate were 57.1%, 57.4%,
13.4%, and 5.0%, respectively. Patients with tracheal inva-
sion and PM1 had prognoses different from those of patients
with extrapulmonary invasion or malignant exudate (Figure
3, B). Surgical curativity was also investigated. Among the
patients with T3 disease, the bronchial invasion group con-
tained a significantly larger number of curative resections
than the extrapulmonary invasion group (Table 5). Among
the patients with T4 disease, the tracheal invasion group and
the PM1 group contained significantly larger numbers of R0
resections (Table 6).
On the basis of these findings, patients with T3 bronchial
invasion who exhibit a relatively good prognosis were re-
classified as having T2 disease, and patients with T4 tra-
cheal invasion, as well as patients with T4 PM1, were
reclassified as having T3 disease. After this reclassification,
the 5-year survivals were again determined, and the results
were 34.4% for patients with T3 disease and 7.3% for
patients with T4 disease, showing a significant difference
between the prognoses of the 2 groups (Figure 4, A). When
the 5-year survivals of the different pathologic stages were
determined by using this new classification, survivals for
patients with stage IIIA disease and patients with stage IIIB
TABLE 2. Cox proportional hazards regression model in
predicting survival of 409 patients
Variables Assigned score Hazard ratio (95% CI) P value
Age (y)
60 0 1.706 (1.185-2.458) .004
60 1
Sex
Male 0 1.584 (1.121-2.237) .009
Female 1
Curativity
R0 0 1.622 (1.012-2.597) .044
R1 or R2 1
Tumor status
T1 1 1.545 (1.295-1.843) .001
T2 2
T3 3
T4 4
Nodal status
N0 0 1.794 (1.543-2.085) .001
N1 1
N2 2
N3 3
CI, Confidence interval.
TABLE 1. Characteristics of the 429 patients with non–
small cell lung cancer
Characteristics No. of patients Percentage
Age (y)
60 115 26.8
60 314 73.2
Sex
Male 286 66.7
Female 143 33.3
Histologic type
Squamous cell
carcinoma
168 39.2
Adenocarcinoma 221 51.5
Large cell carcinoma 17 4.0
Others 23 5.3
Tumor status
T1 160 37.3
T2 157 36.6
T3 40 9.3
T4 72 16.8
Nodal status
N0 283 66.0
N1 37 8.6
N2 97 22.6
N3 12 2.8
Pathologic stage
Stage I 222 51.7
Stage II 55 12.8
Stage III 152 35.4
Curativity
R0 377 87.9
R1 or R2 52 12.1
Total 429 100.0
Curativity was considered as R0 when there was no residual tumor
microscopically, macroscopically, or both.
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disease were 23.1% and 10.2%, respectively, with the dif-
ference being statistically significant (Figure 4, B).
Discussion
The TNM classification was revised and adapted by the
International Union Against Cancer (UICC) in 1997 to
address the problems of heterogeneity of end results within
stage groups and a need for greater specificity in stage
classification.1 This study was conducted after this revision.
Studies evaluating this revised classification have shown
that the prognoses of patients with pathologic stages IA and
IB and the prognoses of patients with stage IIA and IIB
disease are distinct from each other.9 It has often been
reported, however, that no difference was observed between
the prognoses of patients with stage IIIA and stage IIIB
disease according to this classification.3,4 This might be
attributable to the tumor status, T3 and T4 in particular. The
tumor status classifies the tumor according to size and the
extent of invasion. If the nodal status is not taken into
consideration, the surgical curativity should be notably dif-
ferent as you go from T1 to T4 disease. That is to say, it is
expected that patients with T1 and T2 disease include many
curative resection cases, that patients with T3 disease in-
clude many R0 resection cases, and that patients with T4
disease include many R1 or R2 resection cases. The sites of
invasion and metastasis of tumors in patients with T3 and
T4 disease vary widely and consequently, and surgical
curativity also differs. This leads to a diversity of results
within the same T subsets. Curative cases and noncurative
cases exist in R0 cases of T3 disease. Therefore, the surgical
curativity of T3 disease was evaluated as curative or non-
curative. Although this classification is not common, it was
unavoidable for explanation of the surgical curativity in the
patients with T3 disease. On the other hand, R0 cases and
R1 or R2 cases exist in patients with T4 disease, and the
surgical curativity of T4 disease was evaluated as R0 or R1
or R2. In addition, the curativity has been reported as the
only prognostic factor that had a significant effect in all
pathologic stages.2 If patients with T3 and T4 disease were
Figure 2. Postoperative survival curves on the basis of tumor status. There are significant differences in the
prognoses between T1 and T2 groups and between T2 and T3 groups, but there is no tendency of difference
between T3 and T4 groups.
TABLE 3. Cox proportional hazards regression model in
predicting survival of patients with stage III disease
Variables Assigned score Hazard ratio (95% CI) P value
Age (y)
60 0 1.572 (1.013-2.439) .044
60 1
Sex
Male 0 1.241 (0.807-1.909) .325
Female 1
Curativity
R0 0 2.312 (1.297-4.122) .005
R1 or R2 1
Tumor status
T1 1 1.266 (0.967-1.656) .086
T2 2
T3 3
T4 4
Nodal status
N0 0 1.815 (1.377-2.393) .001
N1 1
N2 2
N3 3
CI, Confidence interval.
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reclassified on the basis of the surgical curativity, differ-
ences should become evident between their prognoses.
Originally, patients with T3 and T4 disease were classi-
fied together as having T3 disease in the UICC TNM
classification in 1978.10 They were subsequently subdivided
to better reflect clinical outcomes when the classification
was revised in 1987.11 With the latest revision, it seems that
clinical outcome is still not sufficiently reflected in the
staging, mainly because of heterogeneity of clinical results
in the T3 and T4 subsets. Some patients with respiratory
tract invasion undergo curative resection, even if they have
T3 tumors, or undergo R0 resection, even if they have T4
tumors. Among those with T3 tumors with bronchial inva-
sion in our series, 5 of 8 underwent bronchoplasty, with 3 of
the 5 achieving curative resections. This agrees with some
observations that the prognosis of patients with T3 bron-
chial invasion was relatively good.12 Furthermore, among
those with T4 tumors with tracheal invasion in our series, 6
of 7 underwent tracheobronchoplasty, with 4 of the 6
achieving R0 resections.
In the present study the patients with extrapulmonary
invasion were classified as one group, but there is a possi-
bility that their prognoses varied with the invasion site.
Some investigators have reported that patients with chest
Figure 3. Postoperative survival curves on the basis of the T3 and T4 categories. A, Patients with bronchial invasion
had a tendency to have better prognoses than those with extrapulmonary invasion. B, Patients with tracheal
invasion or PM1 had better prognoses than those with extrapulmonary invasion or malignant exudate.
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wall invasion showed different prognoses, depending on
invasion to the parietal pleura, intercostal muscle layer, and
ribs.13,14 Patients with invasion to the diaphragm have been
reported to have a poor prognosis.15 It is thought that some
T4 tumors with invasion to a large artery or the heart can be
completely resected because of the advances of extended
and combined resection. Consequently, a good prognosis is
expected.
The patients with PM1 (ie, those with a tumor node in the
same pulmonary lobe as the primary focus) are very likely
to undergo R0 resection, and therefore evaluating them as
having T4 disease might contribute to the anomalies in
staging. Some authors16-18 recommend upgrading the tumor
status, as was done in the supplement of the UICC TNM
classification issued in 1993,19 and others20 propose desig-
nating patients with PM1 as having T3 disease. Other in-
vestigators report that the prognosis of patients with PM1
was dependent on the nodal spread and should be reevalu-
ated according to the nodal status.3,17 It is our belief, how-
ever, that the prognosis of patients with PM1 is more
accurately reflected if they were classified as having T3
disease, independent of the nodal status. Other questionable
points are microscopic PM1, synchronous multiple lung
cancer, and metastatic lung cancer, which are detected for
the first time during the postoperative pathologic examina-
tion. The R0 resection rate of microscopic PM1 cases is
thought to be considerably high, with a good prognosis
compared with that of PM2, which is detected on the
opposite side by means of imaging, and PM2 in the pulmo-
nary lobe of the same side, which is detected by means of
perioperative palpation. It is extremely difficult to differen-
tiate synchronic multiple cancer and metastatic lung cancer
from PM.
However, in our study the number of patients in each of
the subgroups was smaller, and more comprehensive liter-
ature reviews of other survival data in these subgroups was
examined (Table 7).12,16,21 As for bronchial invasion, Pitz
and colleagues12 showed that the mean 5-year survival was
greater in 75 patients with tumors located in the main
bronchus (40%) than in 32 patients with tumors with inva-
sion of mediastinal structures (25%). Nakahashi and col-
leages22 found that a 4-year survival of patients with inva-
sion of the main bronchus was 80% and demonstrated that
this subcategory of T3 tumors had a favorable prognosis. As
for tracheal or carinal invasion, Mitchell and colleagues21
showed that the overall 5-year survival of 60 patients un-
dergoing carinal resection, including operative mortality,
was 42%, and patients without lymph node involvement
(N0) had a survival of 51%. These patients performed
carinal resection were classified as having T4 disease with
TABLE 4. Original categories of the patients with T3 and T4 disease on the basis of TNM descriptors
Original categories n TNM descriptors
T3 Bronchial invasion 8 Tumor in the main bronchus less than 2 cm distal to the carina
Tumor-associated atelectasis or obstructive pneumonitis of the entire lung
Extrapulmonary invasion 31 Tumor of any size that directory invades any of the following: chest wall (including superior
sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium
T4 Tracheal invasion 7 Tumor of any size that invades trachea or carina
PM1 22 Tumor with separate tumor nodules in the same lobe
Extrapulmonary invasion 16 Tumor of any size that invades any of the following: mediastinum, heart, great vessels,
esophagus, vertebral body,
Malignant exudate 20 Tumor with malignant pleural effusion, malignant pericardial effusion, or pleural dissemination
One patient with T3 disease with both bronchial invasion and extrapulmonary invasion was excluded.
Seven patients with T4 disease involved in 2 or more categories were excluded.
TABLE 5. Curativities of the original T3 categories on the
basis of TNM descriptors
T3 categories n Curative Noncuraive
Bronchial invasion 8 4 4
Extrapulmonary invasion 31 1 30
Total 39 5 34
Resection was considered as curative when (1) the tumor did not extend
beyond the visceral pleura or the resection line of the bronchus, (2) no
mediastinal lymph node metastasis was detected, and (3) pulmonary
resection with complete dissection of mediastinal lymph nodes was per-
formed. Among the patients with T3 disease, the bronchial invasion group
contained a significantly larger number of curative resections than the
extrapulmonary invasion group (P  .004 by Fisher exact test).
TABLE 6. Curativities of the original T4 categories on the
basis of TNM descriptors
T4 categories n R0 R1 or R2
Tracheal invasion 7 5 2
PM1 22 21 1
Extrapulmonary invasion 16 6 10
Malignant exudate 20 0 20
Total 65 32 33
Resection was considered as R0 when there was no residual tumor
microscopically, macroscopically, or both. Among the patients with T4
disease, the tracheal invasion group and the PM1 group contained signif-
icantly larger numbers of R0 resections (P  .001 by 2 test).
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the current TNM classification, and their survivals were
better than those of other patients with T4 disease. As for
same-lobe intraplumonary satellite or metastasis, Urschel
and colleagues16 retrieved 11 articles and pooled their data
for analysis. They showed that a 5-year survival of 568
patients with satellite nodules in general (primary and ipsi-
lateral nonprimary lobes) was 20% and concluded that the
survival for resected lung cancer with satellite nodules in a
primary lobe was better than that usually observed for T4
(IIIB) disease. All these data might support our present
results.
It is our belief that the tumor status, T3 and T4 in
Figure 4. Postoperative survival curves on the basis of the reclassified tumor status and pathologic stage. A, There
are significant differences of prognoses between T1 and T2 groups, between T2 and T3 groups, and between T3
and T4 groups. B, There is a significant difference between the prognosis of patients with stage IIIA and IIIB
disease.
TABLE 7. Five-year survival of the patients with bronchial invasion, tracheal invasion, and PM1PM2
Categories Authors No. of patients 5-year survival (%)
Bronchial invasion Pitz and colleagues12 32 40
Tracheal invasion Mitchell and colleagues21 60 42
PM1PM2 Urschel and colleagues16 568 20
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particular, should be reviewed if the TNM classification is
revised in the future. A reevaluation of the classification of
patients with PM revised in 19971 and the classification
according to invaded organs is also warranted, the latter
having been hardly revised since 1987.11 Surgical curativity
should be taken into account in such reevaluation. In the
present study attempts were made to reclassify patients with
PM1 and respiratory tract invasion, showing relatively good
surgical curativity with lower stages of disease. It was found
that with the proposed shifts in classification, differences in
prognosis between patients with T3 and T4 disease, as well
as between patients with stage IIIA and IIB disease, become
significant. However, the patients with respiratory tract in-
vasion in our series included many who were eligible for
bronchoplasty or tracheobronchoplasty. This might not re-
flect the general population of patients with respiratory tract
invasion. The ability to perform extended and combined
resection of other invaded organs also confounds the defi-
nition of surgical curativity among various facilities. Con-
sequently, a multicenter study would be a better setting in
which to evaluate the TNM classification as far as this
characteristic is concerned.
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